This, says the company, suggests that infection could be more common among seemingly healthy dogs than vets or owners realise, which may mean there is a greater risk of perioperative bleeding caused by the coagulopathies associated with A. vasorum2 than previously thought.
Elanco says another recent study indicates that there may be a bigger environmental risk for dogs than previously thought, too.
In the study, by Robbins et al, L3 larvae of A. vasorum and Crenosoma vulpis arising from the gastropod intermediate host were found to be immediately infective to dogs and remain so for up to eight weeks, meaning that dogs may only need to lick the molluscs’ slime to be at risk of infection.3
Elanco says this new data means A.vasorum should be added to many differential diagnosis lists, and that pre-operative testing could also be wise.
Jenny Helm, BVMS Cert SAM Dip-ECVIM CA FHEA MRCVS, European Specialist in Small Animal Internal Medicine, said: “Owners need to be aware that healthy dogs could be silently carrying and spreading the disease and that asymptomatic carriers could develop clinical signs at any time.
"They need to be aware that dogs don’t necessarily have to eat slugs and snails to become infected, as recent evidence suggest that other routes of transmission are possible.” To improve data on the prevalence of lungworm, Elanco has developed a version of its lungworm map specifically for veterinary surgeons, where you are invited to upload your cases (including asymptomatic positive cases: www.lungwormmap-vet.co.uk.
For those practices which want to run lungworm awareness campaigns in their area, Elanco has a how-to guide, posters and artwork available to download at www.myelanco.co.uk.
References
The new facility will have 9 consultation rooms and 4 theatres, and is expected to open in early 2022.
It will be Animal Trust’s 10th veterinary hospital – with existing locations in Wrexham, Yorkshire and North England.
Animal Trust now employs more than 300 vets and veterinary care staff.
A further 15 jobs will be created in Rhyl when the new hospital opens.
Owen said: “Our ethos has always been that every animal deserves access to experienced and professional veterinary care as soon as they become ill.
"That’s why we offer free consultations for sick and injured animals brought to our surgeries.
"Our clients are from all walks of life and they come to us because of what we stand for and in some cases, for the prices we offer.
“As a CIC, we try and make sure that a comprehensive veterinary service is within reach of as many pet owners as possible.
"We build large veterinary hospitals that will serve the needs of the local pet-owning community and make a positive impact on their lives.
"Our new surgery will allow us to extend our services to the residents of the North Wales coastline, many of whom currently have to travel to one of our other existing surgeries.”
Funding for Animal Trust was provided by the £500 million Wales Flexible Investment Fund.
Purina says the foods contain adjusted and graded levels of protein and phosphorus to address the delicate balance of providing needed protein in older cats against uraemic toxin production in late phase renal decline.
The current advice is that phosphate should be restricted when the renal patient has confirmed CKD, and IRIS provides therapeutic serum phosphate targets for each stage.
Dr Ellie Groves BA(Hons) VetMB MRCVS, Purina Technical Manager for the UK and Ireland, said: “As obligate carnivores, cats have a high requirement for protein, however, around 20% of senior cats have decreased ability to digest protein, and so are absorbing less protein.
"An inadequate intake of protein leads to loss of lean body mass as muscle is catabolised to meet this need.
"We know that this loss of lean body mass is significantly correlated with an increased risk of mortality.
"But we need to be careful – in renal disease, there is the potential for protein breakdown products to increase in the circulation, acting as toxins.
"So, we need to fine-tune the amount of protein, depending on the stage of chronic renal insufficiency (CRI).
"A dual approach, with Early and Advanced products, allows tailoring of protein levels.”
“Alongside protein, phosphorus content is also tailored to the stage of kidney decline.
"Restricting phosphorus can slow the progression of chronic kidney disease by reducing morphological damage to the kidneys and is thought to be the most important influencer of survival in cats with CKD.
"The levels of phosphorus in the products, are tailored, alongside the protein, to reflect the needs of the cat, with increased restriction when cats are in advanced decline and the kidneys are struggling most.”
NF Renal Function Early Care is available in a dry format (1.5kg) and a pouch (tender pieces with chicken 85g).
NF Renal Function Advanced Care is available in 1.5kg and 5kg packs of dry food, and ‘wet’ options of tender pieces with chicken/ salmon (85g pouches) and a mousse (195g can).
Both diets are now available in veterinary wholesalers.
Dr Power faced a number of charges relating to alleged clinical and communications failings surrounding surgery carried out on two separate dogs on two separate occasions.
The first concerned laryngeal tieback surgery carried out on Harvey, a Tibetan Terrier in March 2018, and the second concerned oesophageal surgery carried out on a boxer dog, Boss, in October 2018.
The College withdrew a number of the charges at the start of the hearing, and more later after hearing from witnesses.
Of the remainder, Dr Power admitted that she had not undertaken pre-operative radiographs before proceeding with the laryngeal surgery, had failed to perform the surgery appropriately (she dissected excessive tissue and had inappropriately placed sutures), and had undertaken the surgery when it was outside her area of competence.
In relation to the oesophageal surgery, Dr Power admitted failing to provide a referral report and/or clinical records to the veterinary practice he was referred from, despite requests from the practice.
The Committee found that the majority of the charges which had not been withdrawn or admitted by Dr Power, not proven.
However, the Committee found that in addition to the admitted charges, Dr Power had subjected the dog undergoing oesophageal surgery to an excessive 9.5 hours of anaesthesia.
The Committee then went on to consider whether the proven charges amounted to serious professional conduct.
Counsel for the College submitted that Dr Power’s conduct breached the part of the Code of Professional Conduct relating to veterinary surgeons keeping within their area of competence and referring responsibly; and providing veterinary care that is appropriate and adequate.
In terms of aggravating factors, the College submitted that there was both actual injury to the animal, as well as actions that posed a risk of injury, that Dr Power financially benefitted from the alleged misconduct as she was paid to perform a procedure outside her competence, and that she occupied a position of increased trust and responsibility as she advertised herself as a practitioner who accepted referrals and was competent to perform soft tissue surgery.
Dr Power’s counsel submitted that the charges that had been found proven amounted to clinical and administrative failings and that this was not a case of a veterinary surgeon deliberately or recklessly acting outside of their capabilities, but rather a case where a diligent and responsible veterinary surgeon had fallen short in discrete areas of her clinical practice and had reasonably believed at the time that she was competent to perform the surgery.
The Committee found that although the conduct within the proven charges fell short of what would be reasonably expected of a veterinary surgeon, it did not fall so far short that her conduct constituted serious professional misconduct.
Paul Morris, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee understood that it had a responsibility to consider the wider public interest, taking into account the view of a reasonable member of the public in possession of all the relevant facts and information.
“The Committee considered that such a member of the public would understand that veterinary surgery is a challenging profession. It was of the view that such a member of the public would not expect perfection, but understand that any professional practitioner may make mistakes in the course of their practice.
“It is the judgement of this Committee that the respondent’s conduct does not constitute disgraceful conduct in a professional respect.”
The full findings of the Disciplinary Committee can be found at www.rcvs.org.uk/disciplinary
The award is to recognise the dedication of the country’s veterinary nurses and the support they give to their veterinary teams, the nation’s pets and pet owners. It is given to a vet nurse who not only cares for sick and injured pets but also encourages responsible pet ownership and improves pet welfare in their community.
The award will be presented at the BVNA Congress on Saturday 2nd October 2021, which will this year be a hybrid event with live speakers at the event in Telford and remote delegates.
David Catlow, Blue Cross Director of Veterinary Clinical Services said: “The veterinary profession faced difficult times for much of the past couple of years but vet nurses strove on to provide their usual professionalism, compassion and special care for pets and their owners.
"Now, more than ever, we need to recognise their invaluable work and the incredible reassurances and support they offer pet owners and how they are dedicated to helping the welfare of the nation’s pets in their communities.”
Last year, the award went to Chloe Mackintosh (pictured right), a veterinary nurse at RSPCA in Harmsworth, North London, who was nominated for her passion and commitment to animal welfare.
If you know a vet nurse who you believe has gone the extra mile for your pet or you believe they have made a significant contribution to animal welfare, complete the nomination form on the Blue Cross website at www.bluecross.org.uk/bvna.
The VMD's ruling sets a chilling precedent for the curtailment of free speech by a Government body.
The ruling came to light after VetNurse.co.uk published an independent video news report relating to the launch of Bravecto Injectable, a new yearly flea treatment for dogs.
The film was neither paid for nor commissioned by the manufacturer, and nor did the maker exercise editorial control over its content.
The film was clearly labelled for and aimed at veterinary professionals, and its intent was not to promote the sale or supply of a prescription medicine, but rather to inform vets and nurses about the new product, albeit in an enthusiastic manner.
It was therefore not an advertisement, but journalism.
The Dictatorship nevertheless argued that it defines any social media content that mentions the brand name of a prescription veterinary medicine and which does not give a balanced overview of all the other treatment options for a given condition, as an advertisement.
This, it said, is regardless of whether content is created by the manufacturer or supplier of drug to promote sales of their product, or any member of the public or journalist who just wants to talk about or report on a prescription medicine publicly without any intent to promote sales.
The Dictatorship's position is that any such content can only appear in spaces dedicated to the appropriate audiences.
Notwithstanding the fact that all of VetSurgeon.org's social media channels are dedicated to the appropriate audiences, it leaves us in the almost laughable position where, according to the VMD, the BBC is allowed to report about powerful prescription medicines for humans in a way that inevitably promotes their supply, but VetSurgeon.org cannot report the launch of ... wait for it ... a flea treatment.
However the VMD then shared its incontinent interpretation of the law in a series of emails in which it was unable to provide a consistent definition of where it would allow content about prescription veterinary medicines to be published.
It first claimed (without any supporting evidence of any law to this effect), that:
"... it would need to be on a closed page which only followers could view would require active confirmation of the follower’s professional status before allowing access."
However, it swiftly backtracked, presumably realising that this definition would require Vet Times to remove most of its content from public view, including actual advertisements for veterinary prescription medicines published by the manufacturer.
When pressed, the VMD changed tack to a rather looser definition:
"Regulation 11(3) of the VMR does allow you to advertise POM-V products at vets and vet nurses, however to ensure this wouldn’t also be considered as advertising to the general public, it would need to be in a closed space, separate from the general public and directed at veterinary healthcare professionals. For example, on a website, or closed social media group."
However, it then presumably realised that Vet Times would still have to remove most of its content because it is not a closed space, and loosened its definition further still.
"Please note that, where an advertisement for POM-V or POM-VPS veterinary medicine appears in a space dedicated to the appropriate audiences this would not be a breach of Regulation 11(1)(a) due to Regulation 11(3) and Regulation 11(5)."
Clearly the Dictatorship was making it up as it went along.
Nevertheless, it threatened VetNurse.co.uk that it would contact TikTok and demand removal of the film.
So what does this matter?
Two reasons.
Firstly, it may just be a report about a flea treatment, but there is an important principle at stake here: it is simply not acceptable for the Government to censor free speech about medicines by journalists or members of the public.
This, you would think, is so blatantly obvious that it calls into question the overall competence of the Veterinary Medicines Directorate.
Secondly, the ruling also demonstrates the VMD's backward-looking, Canute-like view of the world we now live in.
People talk and social media is awash with information about prescription veterinary medicines; just try typing 'Bravecto Injectable' into TikTok.
As we all know much of what you find online is false.
Fighting misinformation online is an un-winnable fight.
So perhaps instead, the VMD should promote the dissemination of accurate information in order to counter the misinformation.
Bear in mind, it is only the VMD's interpretation of the law which dictates that a manufacturer cannot publish information which mentions a brand name or give a balanced overview of all treatment options because it would promote the supply or prescription of a veterinary medicine.
It could equally well be argued that manufacturers publishing strictly factual information, ie devoid of hyperbole, would NOT be intended to promote the supply or prescription, but instead to counter false information and provide owners with information which time-poor vets are not always able to.
That would be a more pragmatic approach which would do far more good than trying to censor independent journalists and the public.
Two equine journals have joined forces to create a free online collection of their recent articles on endocrinology to raise awareness of these common disorders and to provide veterinary surgeons with what they say is a definitive source of references all in one place.
The collection of references published by Equine Veterinary Education (EVE) and Equine Veterinary Journal (EVJ) covers a range of topics within the field of endocrinology and includes authoritative review articles on insulin dysregulation2, glucocorticoids and laminitis3 and paraneoplastic syndromes4.
The initiative has been made possible with the support of British Equine Veterinary Association Trust and has been compiled by leading international authorities on equine endocrinology, Professor Philip Johnson, of University of Missouri and Professor Nicholas Frank of Tufts University, Boston and the University of Nottingham.
They say that equine endocrine disorders, such as Pituitary pars intermedia dysfunction (PPID), are becoming more promptly identified and treated, thanks to ongoing research and advances in diagnosis, pharmacokinetics and management protocols.
PPID, or Cushing's, is a progressive neurodegenerative condition that is more easily recognised in its advanced form in older horses. Surveys show a PPID prevalence rate of up to 22% in horses over the age of 155, with the odds of developing clinical signs associated with PPID increasing by approximately 20% per year after this age.
Insulin dysregulation (ID), characterised by increased insulin response to oral sugars, hyperinsulinaemia and insulin resistance, is identified in both PPID and equine metabolic syndrome (EMS)2. Both PPID and EMS have been linked to the development of recurrent laminitis with subsequent high risk of mortality6. The exact mechanisms which link insulin to laminitis remain to be clarified1 but this online collection highlights several studies, which partially address this important jigsaw7-12.
Best practice for the management of EMS is outlined by Professors Nick Frank and Ray Geor in the December issue of EVE13. The first goal is to induce weight loss, and guidelines for designing diets for obese equids are provided. Exercise and dietary management14 have been shown to reduce the clinical signs and indices of inflammation in equine metabolic syndrome13 - 15, however, further studies are needed to quantify the efficacy of these management changes on long-term outcomes.
The online collection also includes several studies addressing the diagnosis of PPID. The value of plasma adrenocorticotropin hormone (ACTH), when interpreted with seasonally adjusted reference ranges, is discussed by several authors18-20. Professors Frank and Geor advocate it as the most readily accessible test for monitoring PPID cases in a field setting, although they maintain that the thyrotropin- releasing hormone (TRH) stimulation test is more sensitive and therefore has advantages when diagnosing PPID in its early stages13.
Pergolide has emerged as the drug of first choice for treatment of PPID13. While many vets recommend the early introduction of medication in the hope that it may avert the specter of laminitis, at present, there are no trials comparing pergolide with alternatives. Furthermore, there have been no long-term studies to show that horses treated with pergolide before the onset of clinical signs of PPID have better outcomes, including a reduced incidence of developing laminitis, than horses in which treatment is delayed until clinical signs become apparent.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "Better control of PPID and insulin dysregulation should lower the risk of laminitis to help improve the health and longevity of many predisposed horses and ponies.
"Raising awareness of the benefits of early diagnosis and sharing the latest research on these and other associated conditions are imperative to provide horse owners with the best diagnostic and treatment programmes for their horses. However, it is easy to under-estimate obesity: horse owners need to think about improving management of their horses' feeding and exercise in order to avert problems before they become a veterinary issue."
In the study, Fluorescent tagging for environmental surface cleaning surveillance in a veterinary hospital 1, researchers at Ohio State University used a fluorescent dye to tag pre-determined surfaces in a large veterinary teaching hospital.
The dye was invisible to the naked eye, but fluoresced under a blacklight (UV-A source). It could be easily removed by regular cleaning.
Surfaces were tagged and then assessed 24 hours after tag placement to determine whether they had been cleaned. Tagging and assessment took place during non-peak hours in an attempt to eliminate observer bias. The study ran for a period of 5.5 weeks between June and July 2014 and a total of 4984 surfaces were tagged and assessed.
Jason Stull, corresponding author of the paper said: "Overall, 50% of surfaces were adequately cleaned so that the tag was completely removed. Cleaning varied widely by surface/object and hospital location. Of the surfaces designated as having primarily human contact, the equipment cart and door handle to the dog walking area were most frequently cleaned (100%), whilst examination equipment including the otoscope, ophthalmoscope and swivel light handle were the least frequently cleaned (2.3%).
"Of the surfaces designated as having primarily animal contact, the ward cage interior was the most frequently cleaned (89.0%) whilst the dog run interior was the least frequently cleaned (23.1%). In terms of hospital location, the most frequently cleaned area was radiology (77.5%) and the least frequently cleaned area was the small animal treatment area (4.2%)."
The overall proportion of surfaces satisfactorily cleaned was similar to that reported in previous studies, however, the findings for some surfaces and hospital areas differed.2 This demonstrates the importance of veterinary cleaning surveillance in individual practices so that targeted interventions can be implemented.
Nicholas Jeffery, editor of JSAP said: "With health-care associated infections being a persistent problem in human and veterinary medicine, it is important that surfaces and equipment within the veterinary practice are adequately cleaned. This research demonstrates the potential use of a commercial fluorescent dye for veterinary cleaning surveillance to inform hospital cleaning practices."
The full article can be found in the February issue of the Journal of Small Animal Practice which is free for BSAVA members. It can also be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13090
Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Designed to help veterinary teams make clearer, more confident clinical decisions, the flowchart provides a step-by-step approach to diagnosing and managing ear disease in dogs and cats.
Renzo Di Florio, Technical Veterinary Adviser at Krka UK, said: “It takes you through each step, from diagnosis to treatment and long-term management, including identifying cases that might benefit from referral.
"It can also help practices to develop an otitis externa management plan protocol that’s useful for the whole team, and that’s practical and easy to integrate into existing workflows.”
One of the main messages in the flowchart is the central role of cytology in otitis management.
Tim said: “Cytology is essential to assess the level of inflammation and detect the presence of bacteria or Malassezia.
"This helps clinicians make informed decisions about whether antibiotics are truly needed.
"In contrast, culture and sensitivity testing can be misleading when used to guide topical therapy.”
https://www.krka.co.uk/veterinary-knowledge-hub
Whilst there is extensive research into the mental health and wellbeing of veterinary surgeons and veterinary students, far less research has been conducted on this topic with VNs.
The researchers say that despite similarities with vets, the differences in the history, context, education paths, and responsibilities between the professions necessitate a separate study of factors that may have a negative impact on veterinary nurses.
The survey is part of ‘Nursing Matters’, a two-year mixed-methods project, led by the RVC’s Dr Tierney Kinnison, Lecturer in Veterinary Education, and Dr Jackie Cardwell, Associate Professor in Epidemiology, which will attempt to benchmark the profession's mental health and wellbeing, as well as exploring the factors that may lead to poor mental health.
The study aims to identify issues relating to the workplace or educational institutions that can be changed to support VN wellbeing, and to inform the development of supportive and effective clinical teams.
Dr Tierney Kinnison, project leader and Lecturer in Veterinary Education at the Royal Veterinary College, said: “Veterinary nurses are key members of the veterinary clinical team and have received less attention than veterinary surgeons in mental health research to date.
"Responses from any RVN or SVN in the UK, whether they have been directly affected by mental health challenges or not, will be very useful for this research.”
https://rvc.onlinesurveys.ac.uk/nursing-matters
Meanwhile, the BVA has published the results of its latest Voice of the Profession survey which found that 99% of vets have seen pets in the last 12 months which should have been brought to them for treatment earlier, with 91% reporting that financial reasons were the main factor.
52% of vets also said the number of clients reporting difficulty covering the cost of preventative veterinary care for their animal had increased compared to 2021.
This figure rose to 70% when it came to covering the cost of diagnostic care and treatment.
The Dogs Trust survey, which was carried out by YouGov, asked owners how easy or difficult they would find it to pay vet bills of varying amounts.
10% of pet owners said they would find it fairly difficult to pay unexpected vet bill of £100.
5% said they would find it very difficult.
Overall, 13% said they either cannot afford, or are struggling to afford, the costs of owning a dog in the current climate.
Meanwhile, the charity reports it is getting record numbers of owners asking to hand over their dogs: an average 188 handover requests per day in February compared to an average 141 handover requests per day in 2022, which was itself a record-breaking year (ending in over 50,000 rehoming requests).
In response, Dogs Trust has set up dog food banks at some of its rehoming centres across the UK, which are open to anyone struggling to feed their dog.
The charity has also started a petition asking the Chancellor to Paws the VAT on pet food and veterinary services: https://www.dogstrust.org.uk/support-us/campaigns-appeals/cut-vat-petition
When pet owners were asked in the YouGov survey to what extent they would support or oppose the Chancellor removing VAT from vet care and pet food in next Wednesday’s budget, 61% said they would support it, with 36% of those saying they would strongly support it.
www.dogstrust.org.uk
Phacoemulsification uses ultrasonic energy to emulsify and remove the cataract through small incisions on the eye, instead of requiring ophthalmologists to open 180 degrees of the eye.
It also allows for the placement of an artificial intraocular lens for the best possible visual outcome for patients.
This, says Chestergates, significantly reduces recovery time and complication rates compared to traditional methods.
Chestergates has invested over £130,000 in human-grade ophthalmic technology for its phacoemulsification patients, including an Alcon Centurion Vision System with Active Sentry Handpiece, a next-generation operating microscope, portable electroretinography (ReteVet), a Chromatic Pupillary Light Reflex (CPLR) tester and high-frequency ultrasound probes for ocular imaging.
Endika said: “Chestergates is one of the few specialist veterinary hospitals in the region to offer this new technique.
"It allows for safer, more precise removal of cataracts and placement of artificial intraocular lenses - restoring vision with minimal recovery time.
"We hope it will be of great benefit to pets suffering from cataracts across the region.”
Chestergates is offering fixed pricing for its new cataract surgery service using phacoemulsification.
The cost is £4,550 for one eye and £5,550 for both eyes, including all preoperative tests (electroretinography, gonioscopy, ultrasound, blood work), surgery, 24-hour hospitalisation, take-home medications, and 8 weeks of postoperative care.
The event aims to deliver the latest knowledge on parrot nutrition and welfare and provide an opportunity to collaborate on education and potential next steps for research.
The full programme is as follows:
Sarah Hormozi, Head of Science & Education at PFMA said: “We are hoping to make it a worthwhile event, where parrot experts, welfare groups and parrot food industry can share their knowledge and experience.
"Through discussions we will come up with collective decisions and steps forward to improve the health and welfare of parrots that are kept in captivity, especially from a diet and nutrition perspective."
For ticket prices and to register: https://www.pfma.org.uk/pfma-parrot-symposium-2022
Bonqat 50 mg/ml oral solution for cats contains pregabalin, an analgesic, anti-epileptic which has now been licensed for the alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.
Tessie 0.3 mg/ml oral solution for dogs contains tasipimidine and is licensed for the short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
Dômes Pharma points to research which shows that in the UK 1.4 million1 dogs show signs of distress when left alone, and 4.4 million dogs1 show fear of loud noises.
In addition, over 4 million cats2 are not having routine vet checkups each year, with 26%2 of these owners reporting that it is too stressful for their cat or themselves.
Jonathan Hill, UK country manager at Dômes Pharma sid: "Dômes Pharma is excited to be launching two new innovative products to help vets manage cases in this complex area.
"These products expand our portfolio and provide essential options for owners and their pets struggling with these situational related problems."
https://www.tvm-uk.com/the-behavioural-range
Reference
Megan beat more than 100 nominees to win the Land-based and Environment Learner (LBEL) prize and achieve an overall distinction in her qualification towards becoming a registered veterinary nurse.
Megan joined the referral hospital in 2021 as a patient care assistant before deciding to train as a veterinary nurse.
She now aspires to complete the International Society of Feline Medicine Diploma and to become a clinical coach and help future student vet nurses through their qualifications.
Megan said: “I felt honoured to be nominated for the award so to win and be recognised by the wider veterinary profession is amazing."
Floxabactin is indicated for use in dogs with lower UTIs including those associated with prostatitis, upper urinary tract infections caused by Escherichia coli or Proteus mirabilis in dogs, and superficial and deep pyoderma. For cats, the 15 mg dose can be used with upper respiratory tract infections.
Floxabactin is presented in blister packs: 15mg for cats and dogs, plus 50mg and 150mg for dogs.
Dechra Brand Manager Carol Morgan said: “Floxabactin has been developed with the responsible administration of antibiotics in mind. We would always promote only using antimicrobials when an infection has been documented and based on the results of culture and sensitivity testing, and or cytology testing, if applicable.
"Other treatment options should also be considered before the systemic use of antibiotics such as topical treatment for superficial pyoderma."
For more information, visit: https://www.dechra.co.uk/new-from-dechra
In the study titled “Outcomes of treatments for keratomalacia in dogs and cats: a systematic review of the published literature including non-randomised controlled and non-controlled studies”, a systematic review of the current literature was undertaken to determine the evidence base for the various treatments of keratomalacia in dogs and cats.
The aim of the review was to assess the evidence base and identify recommended treatment(s) based on globe survival, visual outcome, and time to resolution (while maintaining a globe).
An online literature search found 18 relevant studies which were then reviewed and assigned a level of evidence base as described in the Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group.
Each study was assessed for type of study described (e.g. retrospective, prospective, controlled, random/non-random, cohort study, case series/study), the number of animals included, criteria for assessing outcome (e.g. vision, corneal clarity, anatomic repair) and duration of follow-up and time to resolution.
Systematic reviews of randomised trials, randomised trials or observational studies with dramatic effects would have provided the most reliable evidence on which to base recommendations for treatment(s) but none were available for inclusion.
Only one study was classified as level 3 evidence (non-randomised controlled trial) and considered the use of corneal cross-linking (CXL) in the treatment of keratomalacia.
Most studies were level four evidence reporting the outcome of a single treatment, with three prospective studies and seven retrospective studies.
The remaining seven studies were level five evidence (mechanism-based reasoning) and were considered not to provide good evidence for answering the particular study question.
The findings of the study suggest that the evidence for improved outcome of one proposed treatment over another proposed treatment for keratomalacia in dogs and/or cats is very weak.
A combination of treatments – both medical and surgical – may be the most appropriate depending on the individual case.
Studies utilising mechanism-based reasoning would suggest that medical treatment with anti-collagenase treatment is a minimum requirement for keratomalacia cases to prevent globe loss through perforation, with associated pain and suffering.
Nicola Di Girolamo, Editor of JSAP, said: “The findings of this study highlight once more the infrequency of randomised controlled trials in the veterinary literature, and the need for such studies to expand the evidence base in this field.
“Focussing on collecting available evidence in well-conducted systematic reviews is a critical step in order to improve accessibility of the literature for general practitioners and specialists alike.”
The full article can be found in the October issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13326. It is open access and can be freely accessed by anyone.
Photo courtesy BSAVA
Alphazium TT contains alphalactalbumin and magnesium, which, according to the company, targets the three main neurological pathways involved in the regulation of mood and emotional balance.
TVM says Alphazium TT is highly palatable, so it can be administered as a treat, making the process stress free for veterinary staff, pets and pet owners.
TVM UK’s product manager Will Peel said: "Behavioural problems are becoming increasingly common in cats and dogs and are these problems are likely to get worse with pet owners going back to work as lockdown measures lift, which could cause further stress and anxiety in pets.
"Alphazium TT can help owners address these problems whilst being highly palatable – therefore also reducing the stress of tablet administration all-round."
For more information and support materials, visit: https://www.tvm-uk.com/alphaziumtt/2520/ or contact your TVM UK Territory Manager.
The survey is conducted every four to five years and asks veterinary nurses to answer questions about a variety of subjects including demographic data (for example, socio-economic background, educational attainment, race/ethnicity, disability), work-related data (for example, employment status, location of workplace, type of workplace, hours of work, position in practice) and information about professional achievement (for example, hours of continuing professional development (CPD) undertaken and extra qualifications earned).
The survey, which is conducted on the College’s behalf by the Institute for Employment Studies, also ask respondents about their views on different aspects of their profession, including career plans, challenges facing the profession, and wellbeing.
This year, the survey also asks for your view of the RCVS, including its values, how it should communicate, and what it should prioritise in future years.
Lizzie Lockett, RCVS CEO (pictured right), said: "The results of the Surveys form a very important ‘snapshot’ of the profession at a given point in time, but they also prove useful for years to come in terms of how the College develops its regulatory and educational policy, the areas it chooses to focus on and the issues it chooses to tackle.
"The ensuing reports are also used by a myriad of other individuals, such as those in academia, government and representative bodies, as well as journalists. It’s therefore really important that we have as accurate a picture as possible. So although completing the Surveys is entirely voluntary, we strongly encourage members of the professions to take the time to complete them. It will, ultimately, help the development of appropriate and supportive policies for your profession."
The centre, which is one of the largest animal hospitals in the UK, offers 14 specialist-led services.
Hospital director Daniel Hogan said: “The new hospital will provide the region with one of the largest and best-equipped veterinary centres in not only the UK, but also throughout Europe, with an extensive range of expertise in a wide variety of disciplines all under one roof.
“There will be seven operating theatres, 16 consultation rooms, recovery suites, lecture halls, a dedicated ICU department and there are plans for a future hydrotherapy suite.
“The facilities also include a cutting-edge imaging suite, comprehensive treatment facilities and a new linear accelerator to assist our illustrious oncology team.
"We also plan to launch our emergency and critical care service in the first half of 2023.”
Southfields says it also aims to lead the industry in terms of staff wellbeing and sustainability.
Daniel said: “The increased size of the hospital will enable us to provide a dedicated staff wellbeing area and offer a range of activities which will benefit our team in both body and mind.
“Along with exercise and relaxation classes such as yoga and boxercise, we will have an education centre which will be able to offer some really exciting qualifications and courses for the wider profession.
“We’ll also be striving to care for both our community by working with Investors in the Environment (iiE) to introduce a bold green initiative to substantially reduce our environmental impact and enhance our sustainability.
https://southfields.co.uk/veterinary-professionals/new-hospital
"We are urgently looking at what these new national lockdowns will mean for veterinary professionals and services, and we are liaising with the Chief Veterinary Officers.
"We aim to issue updated guidance in the coming days but can confirm that we will not be reverting to emergency-only work, as we saw at the start of the first UK-wide lockdown last March.
"Instead, we are developing guidance to support veterinary professionals to carry out work that is essential for public health and animal health and welfare, in the context of the very strong ‘stay at home’ messages from both governments.
"We recognise that this continues to be a very challenging and difficult time for our colleagues, and we want to thank veterinary teams across the UK for continuing to work safely so that we can all play our part in stopping the spread of Covid.
"Once again we thank animal owners for their understanding and ask them to continue to respect their vets’ decisions at this time. The range of services available will vary between practices so that vets can work in Covid-safe ways to keep their colleagues and clients safe."
Mr Dobson was struck off in 2021 after the DC found that he'd carried out an act of veterinary certification after being removed from the Register for non-payment, failed to have professional indemnity insurance in place and failed to respond to requests from the RCVS about these things.
Mr Dobson submitted a restoration application by email at the start of June, but then didn't reply to any further correspondence from the College, didn't provide any detail supporting his application, didn't attend the hearing and didn't contact the RCVS to explain why.
The Committee decided to go ahead with the restoration hearing in Mr Dobson's absence.
It decided that although Mr Dobson's email on 2nd June 2023 did suggest that he accepted the original findings for which he was removed from the Register, there was not enough evidence of remorse or insight into the the failings which led to him being struck off in the first place, or that he had attempted to keep his continuing professional development (CPD) up-to-date or that, if restored, he would pose no risk to animal health and welfare.
Paul Morris, chairing the Disciplinary Committee and speaking on its behalf, said: “The Disciplinary Committee will only restore the name of the applicant veterinary surgeon to the Register where the applicant has satisfied it that he or she is fit to return to unrestricted practice as a veterinary surgeon and that restoration is in the public interest.
“The Committee’s real concerns about this application and this applicant are that it has before it no evidence of any value or substance to satisfy either of these criteria.
"There is no basis on which the Committee could conclude that the applicant is fit to return to unrestricted practice.
"In turn, there is no basis on which the Committee could conclude that it is in the public interest that this applicant’s name be restored to the Register.
“It is of importance to the profession and to members of the public that restorations to the Register should only occur when the applicant has established by clear evidence that the criteria which are set out in the public documents produce by the College have been satisfied.”
He added: “Having regard to the above criteria and its findings on them, the Committee considers that it remains the case that the protection of the public and the public interest requires that his name be not restored to the Register and therefore refuses this application.”
www.rcvs.org.uk/disciplinary
FirstVet says the funding will enable it to expand its service globally, including the United States, Germany, and France. It will also allow it to continue developing its product and introduce new features to improve the experience for pet owners and vets, such as new automation tools and integration with clinics' existing systems.
The latest round of financing takes FirstVet’s total funding to-date to €24.5M.
Founded in 2016 in Sweden, FirstVet currently has a presence in five markets: the United Kingdom, Norway, Denmark, Finland, and its native Sweden. The company says it has over 200,000 registered users and has provided consultations for over 150,000 pets since launch.
Currently, FirstVet consultations are offered free to millions of owners through partnerships with 20 insurance companies across all markets, including Bought By Many in the UK.
Co-founder David Prien said: "FirstVet is the first truly neutral stakeholder in the world to coordinate pet care. In what is a highly privatised industry, our reliable service provides value to the entire sector, and we are growing at an incredible rate."
There's a complimentary counter top unit and pillow packs to help veterinary surgeons and nurses communicate the benefits of probiotics to clients. The unit can hold a cat and dog 30 sachet box of Purina Pro Plan FortiFlora from practice stock and the pillow packs can be used to dispense single sachets, so the client can trial the product with their pet at home.
At the same time, the company is encouraging vets and nurses to look at the evidence behind the probiotics they recommend. Although carried out a while ago now (2003 and 2011), two studies have shown that other diets claiming to contain probiotics generally did not meet the label claim when evaluated1,2.
Libby Sheridan, MVB MRCVS, Purina Veterinary Technical Affairs Manager, UK & Ireland says the efficacy of probiotics is thought to be strain-specific3 and recommends that clinicians critically assess the evidence for the particular strain and preparation of probiotics stocked or used.
Libby said: "The quality and efficacy of probiotics can vary and while in some cases there is strong evidence for efficacy in the targeted species, for others, the evidence is scant. Having experienced it myself, I know it's not always easy when working in a busy practice to take the time to ensure the evidence is there, but the studies back up that we should assess these things carefully before making a robust recommendation to our clients."
Most of the probiotics commercially available to veterinary professionals use the lactic acid bacterium Enterococcus faecium.
The particular strain and preparation of any probiotic will affect its ability to reach the large intestine, the expected site of action, intact. The evidence for the SF68 strain of Enterococcus faecium has been validated in a number of studies4-11 over recent years. Proven benefits of the SF68 strain include those focused on the gastrointestinal system where it supports canine and feline intestinal health and microflora balance and those with wider implications, such as support for a healthy immune system.
To obtain a unit or discuss the science, contact your Purina Veterinary Nutrition Partner or telephone the Purina Veterinary Nutrition Team on 0800 212161 quoting code VETPRESS.